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Abstract
Purpose: Insulin-like growth factor (IGF) signaling through human insulin receptor isoform A (IR-A) contributes to
tumorigenesis and intrinsic resistance to anti-IGF1R therapy. In the present study, we (a) developed quantitative TaqMan
real time-PCR-based assays (qRT-PCR) to measure human insulin receptor isoforms with high specificity, (b) evaluated
isoform expression levels in molecularly-defined breast cancer subtypes, and (c) identified the IR-A:IR-B mRNA ratio as a
potential biomarker guiding patient stratification for anti-IGF therapies.
Experimental Design: mRNA expression levels of IR-A and IR-B were measured in 42 primary breast cancers and 19 matched
adjacent normal tissues with TaqMan qRT-PCR assays. The results were further confirmed in 165 breast cancers. The tumor
samples were profiled using whole genome microarrays and subsequently subtyped using the PAM50 breast cancer gene
signature. The relationship between the IR-A:IR-B ratio and cancer subtype, as well as markers of proliferation were characterized.
Results: The mRNA expression levels of IR-A in the breast tumors were similar to those observed in the adjacent normal
tissues, while the mRNA levels of IR-B were significantly decreased in tumors. The IR-A:IR-B ratio was significantly higher in
luminal B breast cancer than in luminal A. Strong concordance between the IR-A:IR-B ratio and the composite Oncotype DX
proliferation score was observed for stratifying the latter two breast cancer subtypes.
Conclusions: The reduction in IR-B expression is the key to the altered IR-A:IR-B ratio observed in breast cancer. The IR-A:IR-B
ratio may have biomarker utility in guiding a patient stratification strategy for an anti-IGF therapeutic.
Citation: Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, et al. (2011) Altered Expression of Insulin Receptor Isoforms in Breast Cancer. PLoS ONE 6(10):
e26177. doi:10.1371/journal.pone.0026177
Editor: S. K. Batra, University of Nebraska Medical Center, United States of America
Received June 23, 2011; Accepted September 21, 2011; Published October 26, 2011
Copyright:  2011 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: All authors are employees of MedImmune, the funder, which played a role in study design, data collection and analysis, decision to publish, and
preparation of the manuscript.
Competing Interests: All the authors of this manuscript are Medimmune employees and Astrazeneca stock owners. The work presented is entirely funded by
MedImmune. MedImmune is developing an anti-IGF monoclonal antibody. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data
and materials.
* E-mail: YaoY@MedImmune.com
Introduction
The mature human insulin receptor (IR) has two isoforms,
insulin receptor isoform A (IR-A) and insulin receptor isoform B
(IR-B). Both isoforms result from alternative splicing of the same
primary transcript. IR-A differs from IR-B by the exclusion of exon
11, which encodes a 12 amino acid fragment (residues 717–728) of
the insulin receptor a-subunit [1]. The relative abundance of
mRNAs encoding the IR-A and IR-B isoforms is regulated in a
tissue-specific manner [2] and also differs by stage of cell
development and differentiation. IR-A is the predominant isoform
in fetal tissues and cancer cells [3]. The two IR isoforms have been
reported to exhibit distinct functional properties. While IR-B
homodimers are the classical receptors for insulin with metabolic
effects in muscle, liver and adipose tissues, IR-A homodimers can
bind IGF-II and, to a lesser extent, IGF-I, in addition to insulin [4],
[5], [6] and may be involved in mediating the growth promoting
and anti-apoptotic effects of this growth factor under physiological
conditions like embryonic development [3].
The fine regulation of the IR-A:IR-B expression ratio may be
rendered more complex by coexpression of the cognate IGF1R,
which may form hybrid receptors with IRs. Several studies have
demonstrated the existence of IR-A/IGF1R hybrid receptors.
These hybrid receptors are heterodimers comprised of an ab chain
from the IR and an ab chain from the IGF1R, both in normal [7],
[8], [9] and cancer cells [10]. Increased occurrence of these
hybrids can be observed in several tumor cells as the result of IR
and/or IGF1R overexpression [10], [11]. The pharmacological
properties of these hybrids seem to differ from those of their
homodimer counterparts and depend on the IR isoform involved.
The IR-A/IGF1R hybrid receptors are strongly activated by IGF-
I and IGF-II and weakly activated by insulin. By contrast, hybrid
receptors containing IGF1R and IR-B are much less sensitive to
IGF-II and insulin [12]. It is suggested that proliferative IGF
signaling can occur through IGF1R homodimers, IGF1R/IR-A
heterodimers, and IR-A homodimers [6], [13], [14].
As a key signaling component of the IGF pathway, IGF1R is the
target of several investigational agents in clinical development.
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sparing IR-A due to concerns that co-targeting IGF1R and IR
would result in unacceptable toxicity [15]. However, clinical
failures with IGF1R-specific therapy suggest that it may be critical
to inhibit aberrant IR-A signaling in addition to IGF1R. This
assertion has been supported by Ulanet, et al. [15], who showed
that IGF-II signaling through IR-A contributes to tumorigenesis
and intrinsic resistance to anti-IGF1R therapy. Additional work
supporting the importance of IR-A signaling was reported recently
by Gao et al. [16], who described preclinical data using a
monoclonal antibody that sequesters IGF1 and IGF2, thereby
blocking signaling through both IGF1R and IR-A. Results showed
that in response to blocking IGF1 and IGF2, dramatic antitumor
activities were observed in tumors that express both IGF1R and
IR-A or IR-A alone. Similar antitumor activities were not seen in
these tumors when inhibiting IGF1R alone.
As therapeutic strategies for co-targeting IGF1R and IR-A
move forward in clinical development, evaluating IR-A levels in
clinical tumor samples becomes critical for identifying the most
appropriate population to receive IGF-targeted therapy. To date,
the most common method to specifically measure human IR-A and
IR-B expression has been described by Frasca and colleagues [3].
This method is based on PCR amplification and gel separation,
followed by qualitative measurement of the resulting bands. The
method is tedious and lacks quantitative accuracy, which limits its
potential use as a biomarker for clinical development. Due to the
lack of an efficient and accurate method to detect human IR-A and
IR-B mRNA levels, the expression of IR-A and IR-B in cancer
tissues, particularly the IR-A:IR-B ratio, has been difficult to
evaluate. In this paper, we describe the design and implementation
of TaqMan qRT-PCR-based assays to specifically quantify the
levels of IR-A and IR-B transcripts in human breast cancer samples.
Furthermore, we evaluated the ratio of IR-A to IR-B expression in
ER+/PR+ and Her2- breast cancers of different molecular
subtypes. As these subtypes have previously been shown to differ
in proliferation index, response to hormonal therapy, and overall
clinical outcome, the association of the IR-A:IR-B ratio with a
particular subtype may identify patients more likely to respond to
IGF-targeted therapy.
Materials and Methods
Primary Breast Tumor Tissues
Forty-two grade I to III infiltrating breast ductal carcinomas
were purchased from ILSbio (Chestertown, MD). Nineteen of the
42 breast tumor tissue samples had matched normal adjacent breast
tissue (NAT) samples. In the case of breast cancer mastectomy,
normal tissue from the opposite breast was taken and serves as the
normal adjacent tissue. The ages of patients ranged from 31 to 88
years.Allthebreastcancersampleswereestrogenreceptor(ER)and
progesterone receptor (PR) positive and HER2 negative according
to immunohistochemistry. All samples were freshly frozen and
collected before initiation of any treatment. Tumor samples were
macrodissected to remove normal tissue, and tumor purity in all
samples was greater than 85%. Normal samples were macro-
dissected to remove non-glandular tissue.
Breast Cancer Tissue cDNA Arrays
Four breast cancer tissue cDNA arrays (BCRT101, BCRT102,
BCRT103, and BCRT104) were purchased from OriGene Tech-
nologies (Rockville, MD). The arrays contain cDNAs from 15
normal breast tissues (from 10 unique individuals) and 165 unique
breastadenocarcinomatissues.Thetumorstage rangedfrom stage I
to IV and the tissues were comprised of 50–90% tumor.
RNA Extraction
Total RNA was extracted from snap-frozen tissue specimens
using the ZR RNA MicroPrep kit (Zymo Research, Orange, CA).
RNA purity and concentration were determined spectrophoto-
metrically (260/280.1.9). RNA quality was assessed on an
Agilent 2100 Bioanalyzer using the RNA 6000 Nano LabChipH.
Design Real-time Quantitative PCR Primer and Probes for
Insulin Receptor Isoforms
Full-length mRNA transcript sequences for the IR-A (NM_
001079817) and IR-B (NM_000208) isoforms were retrieved from
the NCBI Reference Sequences database. For the IR-A assay
design, we targeted the exon 10/12 junction region for the gene
specific probe; the exon 10 coding region for the forward primer
pairs; and the exon 12 coding regions for the reverse primer pairs.
For the IR-B assay design, we targeted the exon 11 interior coding
region for the gene specific probe; exon 11/12 junction for the
forward primer pairs; and exon 12 for the reverse primer pairs. All
primer/probe designs were imported into the Primer Express
(Applied Biosystems, Foster City, CA) software tool to ensure
optimal design for utilization in the TaqMan Gene Expression
assay procedure. All probes were designed to incorporate a minor
groove binding moiety (MGB), and were labeled with a fluorescent
dye (FAM) for detection and a non-fluorescent quencher. Primers
and probes were custom ordered from Applied Biosystems.
Sequences for all primer/probe combinations are as follows:
IR-A: Thesequenceoftheprobeis59-TCCCCAGGCCATCT -39;
The sequence of the forward primer is 59-TGAGGAT-
TACCTGCACAACG -39;
The sequence of the reverse primer is 59- ACCGTCA-
CATTCCCAACATC -39.
IR-B: The sequence of the probe is 59 CCGAGGACCC-
TAGGC -39;
The sequence of the forward primer is 59- CGTCCCCA-
GAAAAACCTCTTC -39;
The sequence of reverse primer is 59-GGACCTGCGTTTCC-
GAGAT -39.
Positive and Negative Controls for TaqMan assay of IR-A
and IR-B
Commercially available cDNA clones that contain the full-
length cDNA clones of IR-A (cloned in pCMV6-XL4) and IR-B
(cloned in pCMV6-XL5) were purchased from OriGene Tech-
nologies, Inc (IR-A: SKU#. SC311328; IR-B: SKU# SC315880).
The sequence verification of each IR isoform clone was conducted
in-house at MedImmune. The empty plasmids pCMV6-XL4 and
pCMV6-XL5 were used as negative control DNA for IR-A and
IR-B assays, respectively.
TaqMan qRT-PCR Gene Expression Analysis
Standard TaqMan qRT-PCR Gene Expression assays were
conducted in a 384-well format for all primer/probe and template
combinations. Reactions consisted of 5 mL of TaqMan Universal
Master Mix (Applied Biosystems), 0.5 mL of 10x Gene Expression
Assay Mix, and 4.5 mL of varying copy numbers of either the IR-B
or IR-A cDNA clone, for a final volume of 10 mL per well. Each
primer/probe and template combination was repeated at least 3
times. All assay plates were run on an Applied Biosystems 7900HT
detection system using standard settings (cycling program included
10 min incubation at 95uC followed by 40 cycles of 95uC for 15 sec
and 60uC for 1 min). Data values (Cycle Threshold [Ct] values)
were extracted from each assay with the SDS v2.0 software tool
(Applied Biosystems).
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TaqMan Gene Expression assays were purchased from Applied
Biosystems.Theassaysinclude:INSR(AssayID:Hs00961554_m1);
ESR1 (Assay ID: Hs00174860_m1); PGR (Assay ID: Hs01556707_
m1); ERBB2 (HER2, Assay ID: Hs01001580_m1); tumor prolifer-
ation genes (Pike S et al 2004): BIRC5 (Survivin, Assay ID:
Hs00153353_m1), AURKA (STK15, Assay ID:Hs01582073_m1),
CCNB1 (Assay ID: Hs00259126_m1), MKI67 (Assay ID:
Hs01032443_m1), MYBL2 (Assay ID: Hs00942543_m1); and
reference genes: ACTB (Hs99999903_m1), GUSB (AssyID:
Hs99999908_m1), GAPDH (Assay ID: Hs99999905_m1), RPLP0
(Assay ID: Hs99999902_m1), TFRC (Assay ID: Hs99999911_m1).
BioMark
TM Dynamic Array Microfluidics System
The BioMark
TM Dynamic Array (Fluidigm Corporation)
microfluidics system allows for high throughput real-time PCR
(up to 2304 individual reactions per plate), producing high quality
data with low variability and a tight correlation with conventional
RT-PCR. Single stranded cDNA was generated from total RNA
using the SuperScriptH III First-Strand Synthesis SuperMix
(Invitrogen, Carlsbad, CA). cDNA samples were pre-amplified
using TaqMan Pre-Amp Master Mix, according to the manufac-
turer’s instructions. Reactions contained 5 mL of cDNA, 10 mL
Pre-Amp Master Mix and 5 mL of 0.2X gene expression assay mix
(comprised of all primer/probes to be assayed) for a final volume
of 20 mL. Reactions were cycled with the recommended program
for 14 cycles and then diluted 1:5 with TE buffer. Pre-amplified
cDNA was either utilized immediately or stored at 220uC until
processed.
To prepare samples for loading into 48648 dynamic array chips
(Fluidigm), the reaction mix contained 2.5 mL 2X Universal
Master Mix (Applied Biosystems), 0.25 mL Sample Loading Buffer
(Fluidigm Corporation), and 2.25 mL pre-amplified cDNA. To
prepare the primer/probes, the reaction mix contained 2.5 mL
20X TaqMan Gene Expression Assay and 2.5 mL Assay Loading
Buffer (Fluidigm Corporation). Prior to loading the samples and
assay reagents into the inlets, the chip was primed in the IFC
Controller. Five mL of sample prepared as described was loaded
into each sample inlet of the dynamic array chip, and 5 mL of 10X
gene expression assay mix was loaded into each detector inlet. The
chip was placed on the IFC Controller for loading and mixing.
Upon completion of the IFC priming step, the chip was loaded on
the BioMark
TM Real-Time PCR System for thermal cycling (10
min at 95uC followed by 40 cycles of 95uC for 15 sec and 1 min at
60uC). The number of replicates and the composition of the
samples varied depending on the particular experiment, but were
never less than triplicate. Average Ct values were used to
determine sensitivity and specificity of the designed probes. The
average Ct values of all available reference gene assays within a
sample were utilized for DCt calculation.
Microarray Processing
Generation of biotin-labeled amplified cRNA from 75 ng of
total RNA was accomplished with the MessageAmp
TM Premier
RNA Amplification Kit (Ambion, Austin, TX). The concentration
and purity of the cRNA product were determined spectrophoto-
metrically. Fifteen micrograms of each biotin-labeled cRNA was
fragmented for hybridization on Affymetrix Human Genome
U133 Plus 2.0 GeneChipH arrays. All GeneChipH washing,
staining, and scanning procedures were performed with Affyme-
trix standard equipment. Data capture and initial array quality
assessments were performed with the GeneChip Operating
Software (GCOS) tool. Stratagene’s (La Jolla, CA) ArrayAssistH
Lite software was used to calculate probe-level summaries (GC-
RMA and MAS5) from the array CEL files.
Breast Cancer Molecular Subtype Classification
A subset of ER+/PR+ and HER2- primary breast tumors
(n=40) and a subset of matched normal adjacent breast tissue
samples (n=15) were profiled on Affymetrix Human Genome U133
Plus 2.0 GeneChipH arrays. Two of the primary breast samples and
four of the normal adjacent breast tissue samples analyzed on the
Fluidigm platform were not processed on GeneChip due to insuf-
ficient RNA quantity. Breast cancer molecular subtype classification,
with regards to luminal-A and luminal-B subtype, was conducted
utilizing our whole genome array data.
Two methods for determining putative sample classification
were implemented. The first classification method utilized a
published PAM50-gene shrunken centroid classifier [17] for
sample sub-typing (normal, basal-like, HER2, luminal-A, or
luminal-B) purposes. MAS5 normalized GeneChip data was used
for this analysis given that the published classifier was built using
this type of scaled data. The samples were classified according to a
Spearman’s rank correlation (50-gene intensity vector vs. subtype
centroid classifier), where the subtype with the highest correlation
value was assigned to a particular sample. The second method
utilized GC-RMA normalized GeneChip data to identify a panel
of differentially expressed transcripts by a two-sample Welch’s t-
test analysis. Samples were divided into two groups (normal or
tumor) based on pathology assessment prior to conducting the
statistical analysis. Probes displaying a fold change differential .3
and P-value ,1.0610
212 (q-value ,1.0610
211) (n=459 probes)
were used for an unsupervised hierarchical clustering analysis.
Several additional probeset selection thresholds were utilized and
resulted in similar clustering patterns (data not shown).
Results
Sensitivity and Specificity of TaqMan qRT-PCR Assay to
Distinguish IR-A and IR-B
Probe sensitivity was tested by performing IR-A or IR-B
TaqMan qRT-PCR assays starting with 100 pg template stock
solutions of IR-A or IR-B (approximately 10
7 copies of DNA
template). The DNA was serially diluted to 10
24 pg (approxi-
mately 10 copies DNA template). Each sample was tested in
duplicate. The slope of the standard template dilution curve was
determined by plotting cycle-threshold (Ct) values as a function of
the log DNA copy number. The results are shown in Figure 1.
Strong correlations were observed between the log [concentration]
and resultant Ct values for each assay tested with its respective
matching standard template. All regression coefficients (r
2 value)
were $0.999 (P#0.0001). Linearities were maintained in the DNA
concentration ranges described above in both assays, demonstrat-
ing a wide dynamic range and yielding accurate Ct values. The
results indicate that both the IR-A and IR-B assays have the
appropriate sensitivity, and are able to detect the corresponding
isoform to approximately 35 copies of DNA.
The specificity of the assays was also assessed by testing the IR-
A assay in the presence of the IR-B DNA template or, alternatively,
the IR-B assay in presence of the IR-A DNA template. The details
of the testing results are shown in Table S1. The IR-A assay does
notamplifyIR-BDNAtemplateintherangetested(10to10
7copies
of IR-B DNA). Likewise, the IR-B assay does not amplify the IR-A
DNA template in the range tested. In contrast, we found the
commercial Applied Biosystems assays (IR-A: Hs00965956_m1;
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measure each isoform accurately (data not shown).
The assay efficiency was assessed by the slopes of the standard
dilution curves for both assays (Figure 1). The slope is -3.259 for
IR-A and -3.155 for IR-B. The two slopes are very similar,
suggesting only minor differences in probe efficiency.
These TaqMan-based assays have been successfully implement-
ed on the BioMark
TM Dynamic Array (Fluidigm), facilitating their
use in a higher throughput system and demonstrating their
performance across multiple platforms.
Expression of IR-A and IR-B in Breast Cancer
Decreasing IR-B mRNA expression level in tumors. In
order to assess the IR-A and IR-B mRNA expression in breast
cancer, 42 primary breast tissue samples that are ER+,P R + and
HER2-, and 19 matched normal adjacent breast tissues were
evaluated. Random hexamer primed cDNAs were pre-amplified
and assayed for expression levels of total IR, IR-A, and IR-B
transcripts by TaqMan qRT-PCR (Fluidigm). Samples were
normalized to the average of five housekeeping genes as described
in the methods section. The results are shown in Figure 2. The
mean fold change differentials (log2-base scale) 695% CI of IR, IR-
A, and IR-B in normal (n=19) were 0.0060.20, 0.0060.27, and
0.0060.20, respectively. The mean fold change differentials (log2-
base scale) 695% CIof IR, IR-A, and IR-B in tumor (n=42) were -
0.8860.29, -0.0760.33, and -2.0860.29, respectively. A two-tailed
Welch’s t-testanalysis indicated that the mRNAlevelsof IR and IR-
B are significantly lower in breast cancer when compared to normal
breasttissue (P,0.0001). Nosignificantdifferences were observed in
the mRNA levels of IR-A in breast cancer when compared with
normal breast tissue (P=0.450).
Increasing the relative proportion of IR-A in tumors. We
calculated the proportion of IR-A relative to total insulin receptor
composition (IR-A + IR-B) in matched tumor and normal pairs as
determined by a 2
(2DCt) calculation. The results are shown in
Figure 3. The mean IR-A transcript proportions (%)6 95% CI
were 46.60%64.74% and 75.24%65.02% for the normal panel
(n=19) and matched tumor samples, respectively. A paired
sample t-test analysis indicated that a significant increase in the
calculated IR-A proportion in tumor samples exists when
compared to matched normal tissue (P,0.0001). The results
suggest that the significantly decreased IR-B levels in tumor
contribute to an overall increase in the proportion of IR-A in
tumor samples compared to normal tissue.
Ratios of IR-A to IR-B in breast cancer. In order to assess
the mRNA transcript ratios of IR-A and IR-B, we calculated DCt
differentials of IR-A and IR-B in normal and primary breast
tumor samples. The DCt differential (IR-B DCt–IR-A DCt) values
were calculated for all samples utilizing the within-sample
reference gene panel (average Ct) for normalization purposes.
The mean IR-A:IR-B DCt 695% CI were -0.2060.27 and
1.8160.31 in the normal (n=19) and primary tumors (n=42),
respectively. A two-tailed Welch’s t-test analysis identified a
significant difference between normal and tumor samples in
relation to observed IR-A:IR-B DCt (P,0.0001) (Figure 4A). The
results indicate that there is a significant increase in the ratio of IR-
A to IR-B in breast tumors.
To further validate the above results, we assessed mRNA
expression ratios of IR-A and IR-B in an additional breast cancer
tissue panel. PCR arrays containing cDNAs from 15 normal breast
tissues (obtained from 10 independent donors) and 165 unique
Figure 1. IR-A and IR-B assay serial dilution curves. Probe
sensitivity was tested by performing IR-A or IR-B TaqMan qRT-PCR
assays with a serial dilution of approximately 10
7 to 10 copies of
plasmid DNA of either IR-A, IR-B, or an empty vector control. The Y axis
represents cycle-threshold (Ct) values and the X axis represents log DNA
copy number. The slope and regression coefficient (r
2 value) of the
standard dilution curve for the IR-A assay are -3.259 and 0.9992,
respectively. The slope and regression coefficient (r
2 value) of the
standard dilution curve for the IR-B assay are -3.155 and 0.9989,
respectively.
doi:10.1371/journal.pone.0026177.g001 Figure 2. Relative mRNA expression levels of insulin receptor
and its isoforms in primary breast cancer compared to normal
breast tissues. TaqMan gene expression assay determined fold
change differentials (log2-base scale) of INSR (total), IR-A, and IR-B
between normal (n=19) and tumor (n=42) breast tissue samples.
Average normal DCt values were used for calculation of fold change
differentials for each sample. A two-tailed Welch’s t-test analysis
identified a significant difference between normal and tumor samples
for both INSR and IR-B (P,0.001), whereas no difference was observed
for IR-A (P=0.450). Black bars represent the median log2 fold change
value within a particular gene target and tissue-type combination.
doi:10.1371/journal.pone.0026177.g002
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were pre-amplified and assayed for expression levels of IR-A, IR-
B, and ER by TaqMan qRT-PCR (Fluidigm). The DCt
differential (IR-B DCt–IR-A DCt) was calculated for all samples
utilizing the within-sample reference gene panel (ACTB, GUSB,
and GAPDH) for normalization purposes. The results are shown
in Figure 4B. The mean IR-A:IR-B DCt 695% CI was -0.57
60.34 in normal tissues (n=15); and 1.2060.17 across all breast
cancers examined (n=165). We then collected the breast cancer
samples that displayed a 2-fold overexpression of estrogen receptor
relative to normal breast tissue, and compared their IR-A:
IR-B DCt differentials to normal tissue and to all breast cancer
samples. The results are shown in Figure 5. The mean IR-A:
IR-B DCt 695% CI was 1.3960.23 in ER+ breast cancers
(n=83), which is similar to that observed across the whole breast
cancer dataset. A two-tailed Welch’s t-test analysis identified a
significant difference between normal and tumor samples in
relation to observed IR-A:IR-B DCt differential (P,0.0001).
Correlating IR-A:IR-B Ratio with Genes Involved in Breast
Cancer Proliferation
AURKA, BIRC5, CCNB1, MKI67 and MYBL2 are well
characterized genes involved in breast cancer proliferation [18].
The composite expression score of these genes has been used in
Oncotype DX and cell proliferation is the most important factor
contributing to breast cancer recurrence in many patients.
Therefore, we investigated the relationship of the IR-A:IR-B ratio
with the proliferation score in primary breast cancer sample sets
using regression and correlation analyses. Linear regression
analysis was conducted to quantify the relationship between the
calculated IR-A:IR-B DCt differential and a pooled panel of
Figure 3. The proportion of IR-A expression in matched normal
breast and breast cancer specimens. Within sample proportion of
insulin receptor isoform-A (IR-A) relative to total insulin receptor
composition (ie, IR-A + IR-B) as determined by 2
(-DCt) calculation. A
paired sample t-test analysis indicated that a significant difference
exists for calculated IR-A proportion between matched normal and
tumor samples (P,0.001). Black bars represent the median IR-A
proportion (%) within the normal (46.6064.74, mean %695% CI) and
tumor (75.2465.03, mean %695% CI) tissue.
doi:10.1371/journal.pone.0026177.g003
Figure 4. Increasing IR-A:IR-B ratio in primary breast cancer and breast cancer samples from qPCR cDNA array. (A) Calculated DCt
differentials of insulin receptor isoforms IR-A and IR-B in primary breast cancer samples: normal (n=19) and tumor (n=42) breast samples. (B)
Calculated DCt differentials of insulin receptor isoforms IR-A and IR-B breast cancer samples from qPCR cDNA array: normal (n=15), breast cancer
cDNA panels (n=168), and breast tumors from these cDNA panels with .2-fold estrogen receptor over-expression (n=83). DCt differentials (IR-B DCt
- IR-A DCt) values were calculated for all samples utilizing the within-sample reference gene panel (average Ct) for normalization purposes. A two-
tailed Welch’s t-test analysis identified a significant difference between normal and tumor samples in relation to observed IR-A:IR-B DCt differential
(P,0.001). Black bars represent the median IR-A:IR-B DCt.
doi:10.1371/journal.pone.0026177.g004
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MYBL2). Proliferation panel summary values were calculated by
taking the average DCt across all markers for a particular sample.
Summary results for both normal and tumor samples are presented
in Figure5. Thelinear regression analysisresultssuggest a moderate
positive correlation between the two summary values (r=0.78).
These results suggest that the increased proportion of IR-A
observed in tumor tissue may contribute to enhanced proliferation
in ER+/PR+ and HER2- breast cancer.
IR-A:IR-B DCt Differential in Breast Cancer Subtypes
Using mRNA expression profiles, ER+ breast cancers can be
further classified by hierarchical cluster analysis into luminal-A
and luminal-B subtypes [19]. Luminal-A cancers are usually
histologically low-grade and sensitive to endocrine therapy [20].
By contrast, luminal-B cancers are often high-grade and are less
sensitive to endocrine therapy, and have higher proliferation and
poorer prognosis [20], [21]. Creighton, et al. [22] reported that an
IGF-I signature is manifested in luminal-B breast cancers. This
signature is highly correlated with poor prognostic factors and one
of the strongest indicators of disease outcome. To examine the role
of additional components of the IGF signaling pathway in breast
cancer, we investigated the hypothesis that differences in IR-A:IR-
B ratios may be evident when comparing luminal-A and luminal-B
breast cancers.
To address this question we conducted whole genome array
analysis on 40 ER+/PR+ and HER2- negative breast tumors and
15 normal breast samples. We initially utilized a published
PAM50-gene shrunken centroid classifier [17] on our MAS5
normalized GeneChip data as a benchmark for a method that has
been used to partition ER+/PR+ and HER2- negative breast
tumor samples into luminal-A and luminal-B subtypes. Samples
were classified according to a Spearman’s rank correlation, where
the subtype with the highest correlation value was assigned to a
particular sample. IR-A:IR-B DCt differentials in the normal,
luminal-A and luminal-B samples were then compared. The
scatter plot representation of calculated IR-A:IR-B DCt differen-
tials with regards to sample subtype (normal, luminal-A, or
luminal-B) are shown in Figure 6A. The mean IR-A:IR-B DCt
695% CI was -0.2760.34 in normal (n=15); 1.0960.38 in
luminal-A breast cancers (n=13); and 2.1260.39 in luminal-B
breast cancers (n=27). All subtype pair-wise comparisons display
a significant difference (two-sample t-test, P,0.001). The results
indicate that IR-A:IR-B ratios are significantly increased in
luminal-B cancers relative to luminal-A cancers, with the greatest
differential observed between luminal-B and normal breast tissue.
Additionally, we found that these luminal-B samples exhibited a
significant increase in expression of a proliferation gene panel
(data not shown). Increased proportion of IR-A in luminal-B
patients may play an important role in inducing the increased
proliferation observed in this study and others [21].
In addition to the shrunken centroid classifier, we identified an
independent panel of differentially expressed transcripts from our
GeneChip data using a two-sample Welch’s t-test and unsuper-
vised hierarchical clustering analysis. Samples were divided into
two groups (normal or tumor) based on pathology assessments
performed prior to conducting the statistical analysis. Sub-
populations identified were classified as normal, luminal-A, or
luminal-B as a function of transcript panel composition for the
three primary clusters identified. Differentiation of luminal-A and
luminal-B sub-types was primarily determined by over-expression
of proliferation and cell cycle associated genes (e.g. AURKB,
BUB1, CCNA2, CCNE2, E2F7, GTSE1, MKI67, and PKMYT1)
in the putative luminal-B tumors and over-expression of
extracellular matrix associated genes (e.g. ASPN, BGN, CILP2,
MFAP2, and VCAN) in the putative luminal-A tumors. IR-A:IR-
B DCt differentials in the normal, luminal-A and luminal-B were
then compared. The results are shown in Figure 6B. The mean
IR-A:IR-B DCt 695% CI was -0.3260.28 in normal (n=15);
1.0560.20 in luminal-A predicted breast cancers (n=18); and
2.4260.37 in luminal-B predicted breast cancers (n=22). All
subtype pair-wise comparisons display a significant difference (two-
sample t-test, P,0.001).
Overall, an 80% concordance between the two classification
methods implemented was observed, based on our unbiased
assessments. Unfortunately, we are naı ¨ve to the true sub-type
classification of the tumor samples so it is difficult to resolve
differences in classification between the two methodologies.
However, the overall concordance between the results from
comparisons of the IR-A:IR-B DCt differential with both the
published PAM50 classifier and an independent gene selection and
clustering method further supports our observation that the IR-
A:IR-B ratio is significantly increased in the luminal-B subtype of
breast cancer.
Discussion
We have described specific TaqMan qRT-PCR-based assays
that accurately measure the mRNA levels of human IR isoforms
IR-A and IR-B. In the absence of specific reagents to
quantitatively distinguish the two isoforms, previous research
utilized an RT-PCR/gel quantification protocol to distinguish IR-
A and IR-B and measure their relative amounts in normal and
cancer tissues [3]. The TaqMan assays we have developed provide
a significant improvement in sensitivity, reproducibility, and
Figure 5. Correlation of IR-A:IR-B DCt differential with the
expression of proliferation genes. Linear regression analysis of the
relationship between calculated IR-A:IR-B DCt differential (X axis) and a
pooled panel of proliferation markers (AURKA, BIRC5, CCNB1, KI67, and
MYBL2) (Y axis). Proliferation panel summary values were calculated by
taking the mean –(DCt) across all markers for a particular sample.
Summary results for both normal and tumor samples are presented.
The linear regression analysis results suggest a positive correlation
between the two summary values (r=0.78).
doi:10.1371/journal.pone.0026177.g005
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successfully transferred to the BioMark
TM Dynamic Array
(Fluidigm) platform for high throughput applications, suggesting
that migration to an applicable clinical testing platform is also
possible. Additionally, preliminary results indicate that we can
successfully implement these assays on FFPE samples due to the
relatively small amplicon size of each assay (data not shown). Since
FFPE is the clinical standard for cancer diagnosis, examining
samples in this manner will allow for high-throughput and
sensitive quantitation of IR-A:IR-B ratios over what is typically
a long course of clinical care and also help identify the subset of
patients with altered IR-A:IR-B ratios that might respond to IGF-
targeted therapy.
Over-expression of hybrid IGF1R and IR-A receptors has been
reported in breast cancer [23], but owing to technical difficulties in
quantifying IR-A and IR-B in large numbers of clinical samples,
the overall expression levels of IR-A and IR-B in breast cancer
relative to normal breast tissue were not fully known. Our analysis
of primary breast cancer samples indicated that IR-A mRNA
expression levels in the breast tumors were similar to the levels
observed in adjacent normal breast tissues, while the mRNA
expression levels of IR-B were largely decreased when compared
to the adjacent normal breast tissues. Our observation of an
increased IR-A:IR-B ratio in breast cancer tissue relative to
normal is consistent with what has been seen previously; however,
our results are distinct in that we identified a reduction in IR-B
expression as the key to this altered ratio. Given the link between
altered expression of IR isoforms and resistance to the EGFR
inhibitor gefitinib [24], it is clear that aberrant expression levels of
IR-A and IR-B may have significant functional effects on cancer
progression.
The functional consequences of an altered IR-A:IR-B ratio on
cancer progression may also be mediated, in part, by changes in
receptor dimerization patterns and the subsequent effect on cell
signaling pathways. An increase in the relative abundance of IR-A
might significantly increase formation of IGF1R and IR-A hybrid
receptors, IR-A/IR-B heterodimers, and IR-A homodimers in
breast cancer tissues. These changes in dimerization patterns could
result in an increased number of binding sites for IGFs, leading to
increases in mitogenic signaling in breast cancer cells [23], as well
as changes in gene expression strongly associated with cell
proliferation, metabolism, and DNA repair [22]. Of the genes
altered in response to IGF stimulation, the mRNA expression
levels of proliferation genes are most closely correlated with
clinical outcomes [18], [25], [26]. Our data illustrate a positive
correlation between the IR-A:IR-B DCt differential and the
proliferation score. These data also provide supporting evidence
that the increasing IR-A proportion may contribute to the tumor
proliferation phenotype of breast cancers.
Gene expression profiling studies have consistently revealed
biologically distinct breast cancer subtypes with different progno-
ses and treatment responses [27]. At the molecular level, ER+/
PR+ and HER2- breast cancer can be further divided into
luminal-A and luminal-B subtypes [19]. The luminal-B subtype is
characterized by a cell proliferation signature that includes the
expression of MKI67, CCNB1, and MYBL2, which have been
associated with tamoxifen resistance [21], [28]. The luminal-A
subtype, by contrast, is characterized by lower proliferation,
response to hormonal therapy and relatively good prognosis. In
this study we found a positive correlation between IR-A:IR-B DCt
differential and the expression of multiple proliferation genes, as
well as a more prominent IR-A:IR-B DCt differential in luminal-B
breast cancers classified according to conventional methods.
Therefore, our findings support the assertion that the significant
increase of IR-A:IR-B ratio in luminal-B patients may be related
to the high proliferation and poor prognosis observed for this
subtype. The luminal-B subtype has been clinically associated with
higher grade, larger tumor size, positive lymph node involvement,
increased lymphovascular invasion, and poorer relapse-free
survival [29]. Furthermore, breast cancer patients with luminal-
B tumors are at increased risk for relapse and death, despite
endocrine therapy [29]. The association of increased IR-A:IR-B
Figure 6. IR-A:IR-B DCt differential in subtypes of ER+ breast cancer. Scatter plot representation of calculated IR-A:IR-B DCt differentials with
regard to sample subtype (normal, luminal-A, or luminal-B) classification determined by a shrunken centroid classifier-based methodology (A) and a
hierarchical clustering analysis (B). All subtype pair-wise comparisons display a significant difference (two-sample t-test, P,0.001). Black bars
represent the median IR-A:IR-B DCt differential within a particular sample subtype.
doi:10.1371/journal.pone.0026177.g006
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could potentially respond to therapy that co-targets IGF1R and
IR-A. Moreover, it highlights the potential importance of targeting
IR-A in this subgroup of patients and suggests that therapeutic
strategies designed to target the growth factors IGF1 and IGF2
themselves, may be more successful than strategies targeting the
IGF1R only.
Previous work has shown that protein levels of the total insulin
receptor are elevated in breast cancer tissue compared to normal
breast tissue [30] and that insulin itself may affect tumor
progression by acting through its own receptor [31]. Specifically,
Papa et al. [30] reported the average protein expression level of
the insulin receptor was elevated approximately six-fold in 159
breast cancer tissues when compared to 27 normal breast tissues.
These results appear to contradict our results, which suggest that
total insulin receptor transcript levels are lower in breast cancer
tissue when compared to normal breast tissues. However, in a
subsequent manuscript from the same group [31], total insulin
receptor protein levels were shown to be elevated in 2 of 3 breast
cancer cell lines, but no quantitative difference in insulin receptor
mRNA content was observed in these same cell lines. This suggests
that post-transcriptional mechanisms could play a role in
regulating the total protein level of insulin receptor in cancer. In
contrast, relative increases in the mRNA expression ratio of IR-A
and IR-B has been observed in dedifferentiated thyroid carcino-
mas [32] and associated with characteristics of stemness and the
development of thyroid cancer [33]. Therefore, alterations in the
IR-A:IR-B transcript ratio observed in this study could signifi-
cantly increase our understanding of the role of insulin receptor
isoforms in breast cancer, independent of the total insulin receptor
content in these tumors.
In summary, the specific TaqMan qRT-PCR-based assays that
we developed can easily be incorporated into routine clinical
practice and measure the relative abundance of IR-A and IR-B
mRNAs in human tissues with high sensitivity and specificity.
Studies based on these assays may provide value in evaluating the
therapeutic benefit of targeting both IGF1R and IR-A pathways
by inhibiting the growth factors IGF1 and IGF2, as well as
potentially identifying patients more likely to respond to any anti-
IGF therapy under clinical development. The results reported here
provide a promising foundation to support these future efforts.
Supporting Information
Table S1 Specificity of IR-A and IR-B assays. Assay
specificity was tested by performing IR-A, IR-B, and IR qRT-
PCR assays with a serial dilution of approximately 107 to 10
copies of plasmid DNA of IR-A and IR-B. Cross reactions of
either IR-A assay to IR-B DNA or IR-B assay to IR-A DNA were
not observed.
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